South Koreans vote in historic election

May 9, 2017

Seoul, May 9: South Koreans went to the polls today to choose a new president after Park Geun-Hye was ousted and indicted for corruption, and against a backdrop of high tensions with the nuclear-armed North. Voters have been galvanised by anger over the sprawling bribery and abuse-of-power scandal that brought down Park, which catalysed frustrations over jobs and slowing growth.

Koreans

Left-leaning Moon Jae-In, a former human rights lawyer, has held a commanding lead in opinion polls for months, with the final Gallup Korea survey before a week-long pre-election blackout giving him 38 percent support, followed by former tech mogul Ahn Cheol-Soo on 20 per cent.

"I feel the people's strong will to change the government... We can make it a reality only when we vote", Moon said after casting his ballot with his wife at a polling station in western Seoul. Hong Joon-Pyo, of Park's Liberty Korea party, who languished in third place in the 13-strong field on 16 percent, urged voters to support him, branding Moon as a "pro-Pyongyang leftist".

Chung Tae-Wan, a 72-year-old doctor, cast his ballot at a polling station in the prosperous Seocho district of the capital. "I voted for Hong, as security (against North Korea) is the most important thing", he told AFP. Kim Kyung-Min, 24, said she cast her ballot in advance last week. "I was so disappointed in Park and the establishment", she told AFP, but refused to say whom she voted for.

More than 139,000 voting stations opened at 6 am local time (2100 GMT) across the country under overcast skies, with turnout expected to hit a record high. Exit poll results will be available immediately after voting closes at 8 pm (11:00 GMT).

The campaign has focused largely on the economy, with North Korea less prominent, but after a decade of conservative rule a Moon victory could mean a sea change in Seoul's approach towards both Pyongyang and key ally Washington.

The 64-year-old -- who is accused of being soft on the North by his critics -- has advocated dialogue to defuse tensions and to bring it to negotiations, and is seen to favour more independence in relations with the US, Seoul's security guarantor with 28,500 troops in the country.

Seoul needs to "take the lead on matters in the Korean peninsula" and South Koreans should not "take the back seat", he said in a recent media interview. The North has carried out two nuclear tests and a series of missile launches since the start of last year in its quest to develop a missile capable of delivering a nuclear warhead to the US mainland.

Washington has said military action was an option, sending fears of conflict spiralling. More recently US President Donald Trump has softened his message, saying he would be "honoured" to meet the North's leader, Kim Jong-Un.

Moon has also said he would be willing to visit Pyongyang to meet Kim and advocated resumption of some of the inter- Korea projects shuttered by his predecessors, including the Kaesong joint industrial zone. But for many South Korean voters, corruption, slowing growth, unemployment, and even air pollution from China top the list of concerns.

South Korea's rapid growth from the 1970s to 1990s pulled a war-ravaged nation out of poverty but slowed as the economy matured, and unemployment among under-30s is now at a record 10 per cent.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 25,2020

Beijing, Mar 25: Around 5,000 people have signed up for the phase I clinical trial of recombinant novel coronavirus vaccine in Chinese city Wuhan where the virus first emerged late last year.

The recruitment for participants ended this week with nearly 5,000 volunteers signing up for the trial, state-run Beijing News reported on Wednesday.

A single-centre, open and dose-escalation phase I clinical trial for recombinant novel coronavirus vaccine (adenoviral vector) will be tested in healthy adults aged between 18 and 60 years, according to the ChiCTR (China Clinical Trial Register).

The trial, led by experts from the Academy of Military Medical Sciences, gained its approval on March 16 and the research is expected to last half a year.

Requiring at least 108 participants, the trial will be conducted in Wuhan, capital of Hubei province, the region worst-affected by the virus in the country, state-run China Daily reported.

Participants will experience 14-day quarantine restrictions after being vaccinated and their health condition will be recorded every day.

Chinese scientists are hastening the development of COVID-19 vaccines through five approaches --- inactivated vaccines, genetic engineering subunit vaccines, adenovirus vector vaccines, nucleic acid vaccines and vaccines using attenuated influenza virus as vectors.

So far, most teams are expected to complete preclinical research in April and some are moving forward faster, Wang Junzhi, an academician with the Chinese Academy of Engineering said.

Wang noted that research and development of COVID-19 vaccines in China is not slower than foreign counterparts and has been carried out in a scientific, standardised and orderly way.

China has stepped up the process to finalise vaccines to counter COVID-19 after Kaiser Permanente research facility in Seattle and Washington stole the march and began human trials.

China lifted tough restrictions on the Hubei province on Wednesday after a months-long lockdown as the country reported no new domestic cases.

But there were another 47 imported infections from overseas, the National Health Commission said. In total, 474 imported infections have been diagnosed in China -- mostly Chinese nationals returning home.

Comments

Y UDAYA CHANDAR
 - 
Monday, 13 Apr 2020

Dear Sir,

 

I am 77 but a very healthy person with remarkable immunity. I contracted Malaria fever in 1994 because of mosquito biting and I have not been sick anytime there after, not even for ordinary fever in the last 26 years.

 

I am sure you would like to conduct the trials on persons of varying criteria. I am sure you don't want to carry out the trials on perfectly healthy young individuals only. 

 

I am certain that  you want to try the vaccine on a 'common man' from 'general public.' I am ready for the trial and you can take me. I will be delighted. 

 

If you are not handling this matter kindly forward this mail to the correct agency.

 

I look forward to hearing from you.

 

Best regards.

 

If you are not moving forward, you are really moving backward.

Y Udaya Chandar

 

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 6,2020

May 6: In a first, a Pakistani Hindu youth has become the first person from the minority community to join the Pakistan Air Force.

Rahul Dev has been recruited as a General Duty Pilot Officer, the Pakistan Air Force (PAF) said in a tweet.

Dev hails from Tharparkar district of Sindh province.

Sharing the picture of the young man, the PAF recently tweeted, "Good news during #COVID19 tense situation. Thar rocked again...Congratulations #RahulDev who hails from very remote village of Tharparkar has been selected as GD Pilot in #PAF."

Though Dev's exact age is not known, those inducted in PAF at his level are often around 20.

The official Radio Pakistan on Wednesday said it is "for the first time in Pakistan's history" that a Hindu youth has been recruited as a general duty pilot officer in PAF.

The Express Tribune in a report published on Wednesday said the induction showed that the PAF was breaking barriers.

Last year, Kainat Junaid became the first woman from Khyber-Pakthunkhwa province to have been selected for fighter pilot training.

Junaid not only secured the top position in PAF's test for General Duty Pilot, but also became Pakistan’s first female fighter pilot to serve the country alongside her father.

Her father Ahmed Junaid is a Squadron Leader in the PAF.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.